188 related articles for article (PubMed ID: 37421908)
1. Utility of
Chen X; Bai G; Zang R; Song P; Bie F; Huai Q; Li Y; Liu Y; Zhou B; Bie Y; Yang Z; Gao S
Transl Oncol; 2023 Sep; 35():101725. PubMed ID: 37421908
[TBL] [Abstract][Full Text] [Related]
2. Utility of
Zhuang F; Haoran E; Huang J; Wu J; Xu L; Zhang L; Li Q; Li C; Zhao Y; Yang M; Ma M; She Y; Chen H; Luo Q; Zhao D; Chen C
Lung Cancer; 2023 Apr; 178():20-27. PubMed ID: 36764154
[TBL] [Abstract][Full Text] [Related]
3. Dynamic
Chen ZY; Fu R; Tan XY; Yan LX; Tang WF; Qiu ZB; Qi YF; Li YF; Hou QY; Wu YL; Zhong WZ; Jiang BY
Thorac Cancer; 2022 Sep; 13(17):2524-2531. PubMed ID: 35822254
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive
Cui Y; Lin Y; Zhao Z; Long H; Zheng L; Lin X
Front Immunol; 2022; 13():994917. PubMed ID: 36466929
[TBL] [Abstract][Full Text] [Related]
5. The efficiency of
Tao X; Li N; Wu N; He J; Ying J; Gao S; Wang S; Wang J; Wang Z; Ling Y; Tang W; Zhang Z
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1209-1219. PubMed ID: 32043180
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of
Yin X; Li J; Chen B; Liu K; Hu S
Lung Cancer; 2023 Dec; 186():107389. PubMed ID: 37820538
[TBL] [Abstract][Full Text] [Related]
7. Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors.
Kudura K; Ritz N; Kutzker T; Hoffmann MHK; Templeton AJ; Foerster R; Kreissl MC; Antwi K
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551581
[TBL] [Abstract][Full Text] [Related]
8. The role of
Wang G; Zhang W; Luan X; Wang Z; Liu J; Xu X; Zhang J; Xu B; Lu S; Wang R; Ma G
Front Immunol; 2023; 14():1151967. PubMed ID: 37215117
[TBL] [Abstract][Full Text] [Related]
9. Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Han X; Wang M; Zheng Y; Wang N; Wu Y; Ding C; Jia X; Yang R; Geng M; Chen Z; Zhang S; Zhang K; Li Y; Liu J; Gu J; Liao Y; Fan J; Shi H
Eur Radiol; 2024 Apr; 34(4):2716-2726. PubMed ID: 37736804
[TBL] [Abstract][Full Text] [Related]
10. The role of
Wang X; Yang W; Zhou Q; Luo H; Chen W; Yeung SJ; Zhang S; Gan Y; Zeng B; Liu Z; Feng S; Zhang X; Cheng C
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4241-4251. PubMed ID: 35732974
[TBL] [Abstract][Full Text] [Related]
11. [
Vos JL; Zuur CL; Smit LA; de Boer JP; Al-Mamgani A; van den Brekel MWM; Haanen JBAG; Vogel WV
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2010-2022. PubMed ID: 34957526
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
Li C; Wu J; Jiang L; Zhang L; Huang J; Tian Y; Zhao Y; Liu X; Xia L; E H; Gao P; Hou L; Yang M; Ma M; Su C; Zhang H; Chen H; She Y; Xie D; Luo Q; Chen C
Cancer Immunol Immunother; 2023 Mar; 72(3):783-794. PubMed ID: 36056951
[TBL] [Abstract][Full Text] [Related]
13. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
14. [
Yang M; Li X; Cai C; Liu C; Ma M; Qu W; Zhong S; Zheng E; Zhu H; Jin F; Shi H
Eur Radiol; 2023 Dec; ():. PubMed ID: 38127071
[TBL] [Abstract][Full Text] [Related]
15. The Value of
Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
[TBL] [Abstract][Full Text] [Related]
16. Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade.
Wang S; Yuan P; Mao B; Li N; Ying J; Tao X; Tang W; Zhang L; Geng X; Zhang F; Xue Q; Wu L; Zhang H; Gao S; He J
NPJ Precis Oncol; 2022 Jan; 6(1):2. PubMed ID: 35027673
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis.
Deng H; Zhao Y; Cai X; Chen H; Cheng B; Zhong R; Li F; Xiong S; Li J; Liu J; He J; Liang W
Crit Rev Oncol Hematol; 2022 Feb; 170():103582. PubMed ID: 35031441
[TBL] [Abstract][Full Text] [Related]
18.
Hu B; Chen W; Zhang Y; Shi H; Cheng D; Xiu Y
Ann Nucl Med; 2020 May; 34(5):322-328. PubMed ID: 32130663
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity and specificity of amide proton transfer-weighted imaging for assessing programmed death-ligand 1 status in non-small cell lung cancer: a comparative study with intravoxel incoherent motion and
Meng N; Fu F; Sun J; Feng P; Luo Y; Wu Y; Li X; Yuan J; Yang Y; Liu H; Wang Z; Wang M
Quant Imaging Med Surg; 2022 Sep; 12(9):4474-4487. PubMed ID: 36060584
[TBL] [Abstract][Full Text] [Related]
20. Predictive Ability of
Kiyoto S; Sugawara Y; Hosokawa K; Nishimura R; Yamashita N; Ohsumi S; Mochizuki T
Asia Ocean J Nucl Med Biol; 2016; 4(1):3-11. PubMed ID: 27904868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]